US 12128015
APE/REF1 inhibitors for the treatment of cancer
granted A61KA61K31/165A61P
Quick answer
US patent 12128015 (APE/REF1 inhibitors for the treatment of cancer) held by The Regents of the University of California expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Regents of the University of California
- Grant date
- Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K31/165, A61P, A61P35/00